NEO100 not checked

Neonc Technologies, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
3 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“NEO100 is a purified form (\>98.5%) of the naturally occurring monoterpene perillyl alcohol. NEO100 drug product is a non-sterile solution for intranasal administration. It is compounded as a 10% solution in a 50:50 mixture of ethanol:glycerol.”In the company’s words, NCT06357377 on ClinicalTrials.gov
Tested for
Residual, Progressive or Recurrent Grade II or III Meningioma, Glioblastoma Multiforme, Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem, Pineocytoma, Choroid Plexus Carcinoma, Childhood and 2 more
Main trialPhase 2
“This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle until disease progression, death or patient withdraw from study…”In the company’s words, NCT05023018 on ClinicalTrials.gov
Other names
Perillyl alcohol

Other drugs for Residual, Progressive or Recurrent Grade II or III Meningioma

All 76 drugs for Residual, Progressive or Recurrent Grade II or III Meningioma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 30 Dec 2026 NEO100 and High-Grade Meningioma
Phase 1/2Active, not recruiting 30 Nov 2026 Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Phase 1Recruiting Jun 2027 A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow NEO100

Following is part of Solo: you see every change to NEO100 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in